Mounjaro Dose Titration Guide UK: 2.5mg to 15mg

Dose titration is the process of gradually increasing your Mounjaro (tirzepatide) dose from the starting level to the therapeutic maintenance dose. This process is not optional — it is a critical component of safe and effective treatment.

Why titration matters: - GLP-1/GIP receptor agonists cause significant gastrointestinal side effects if started at full dose - Gradual increases allow your body to adapt to the medication - Nausea, vomiting and diarrhoea are dramatically reduced with proper titration - Patients who titrate properly are more likely to stay on treatment long-term - Rushing titration is the single most common cause of treatment discontinuation

The standard Mounjaro titration schedule: - Weeks 1–4: 2.5mg weekly (starting dose) - Weeks 5–8: 5mg weekly - Weeks 9–12: 7.5mg weekly - Weeks 13–16: 10mg weekly - Weeks 17–20: 12.5mg weekly - Week 21+: 15mg weekly (maximum dose)

Each dose level is maintained for a minimum of 4 weeks before increasing. The minimum titration period from 2.5mg to 15mg is therefore 20 weeks (approximately 5 months).

Important UK context: - The MHRA-approved titration schedule should be followed as prescribed - Your prescriber may recommend longer periods at certain doses based on your response - Never increase your dose without consulting your prescriber - The pen devices come in specific dose configurations — you cannot dial intermediate doses

Each dose increase brings changes in both efficacy and side effects. Here is what UK patients typically report at each stage.

2.5mg (Weeks 1–4): - This is primarily an adaptation dose — significant weight loss is not expected - Mild appetite reduction in most patients - Some patients notice no effect at all (this is normal) - Common side effects: Mild nausea (30–40%), decreased appetite, occasional constipation - Weight loss: 0–2kg is typical during this phase

5mg (Weeks 5–8): - Most patients begin to notice meaningful appetite suppression - Weight loss typically accelerates - This is where many patients first experience the "food noise" reduction that Mounjaro is known for - Side effects may increase briefly after the dose change then settle - Weight loss: 1–3kg over these 4 weeks is typical

7.5mg (Weeks 9–12): - Significant appetite reduction for most patients - Some patients find this dose sufficient and may not need further increases - GI side effects may recur briefly after the increase - Energy levels typically stabilise after initial adjustment - Weight loss: 1.5–3kg over these 4 weeks

10mg (Weeks 13–16): - Strong appetite suppression in most patients - Many UK prescribers consider this the "sweet spot" for efficacy vs side effects - Approximately 40–50% of patients achieve satisfactory results at 10mg - Weight loss rate may plateau slightly before the next increase

12.5mg and 15mg (Weeks 17+): - Maximum appetite suppression - Additional weight loss but with diminishing returns vs side effects - Not all patients need or tolerate the maximum dose - The difference between 10mg and 15mg in clinical trials was approximately 3–5 percentage points of additional weight loss

Side effects are most common during the first 1–2 weeks after each dose increase. Knowing how to manage them makes the process much more tolerable.

Nausea (most common): - Affects 20–30% of patients at each dose increase - Usually peaks in the first 3–5 days after increasing - Management strategies: - Eat small, frequent meals rather than large ones - Avoid fatty, greasy or heavily spiced foods - Ginger tea or ginger biscuits can help - Eat slowly and stop before feeling full - Stay hydrated — dehydration worsens nausea - If severe, your prescriber may recommend anti-emetics (cyclizine or ondansetron)

Constipation: - Affects 10–15% of patients - GLP-1 agonists slow gut motility, which can cause constipation - Management: Increase fibre intake gradually, drink at least 2 litres of water daily, consider a gentle osmotic laxative (macrogol) if persistent - Regular physical activity helps maintain gut motility

Diarrhoea: - Affects 10–15% of patients, sometimes alternating with constipation - Usually self-limiting within a few days of each dose change - Maintain hydration with electrolyte drinks

Injection site reactions: - Mild redness, itching or bruising at the injection site - Rotate injection sites (abdomen, thigh, upper arm) - Allow the pen to reach room temperature before injecting - Use a different quadrant of the abdomen each week

Fatigue: - Some patients report tiredness in the first week of a new dose - Typically resolves as the body adapts - Ensure adequate calorie intake — very low calorie intake combined with Mounjaro can cause significant fatigue - If persistent, request blood tests to check thyroid function and iron levels

Not every dose increase goes smoothly, and knowing when to pause titration is as important as knowing the schedule.

Signs you should hold at your current dose (not increase): - Persistent nausea lasting more than 2 weeks at the current dose - Weight loss is already satisfactory at the current dose (0.5–1kg per week) - Vomiting more than twice per week - Difficulty maintaining adequate nutrition - Your prescriber recommends a longer stabilisation period

Signs you should contact your prescriber urgently: - Severe, persistent vomiting (risk of dehydration) - Abdominal pain that is severe or does not resolve - Signs of pancreatitis: severe upper abdominal pain radiating to the back, with nausea - Signs of bowel obstruction: inability to pass gas, severe bloating, no bowel movements for 3+ days with pain - Allergic reaction: rash, swelling, difficulty breathing - Symptoms of low blood sugar (if diabetic): shaking, sweating, confusion

Can you reduce your dose if side effects are intolerable? Yes. Discuss with your prescriber. Dropping back one dose level (e.g. from 10mg to 7.5mg) is a common and perfectly acceptable approach. You can then try re-titrating after 4–8 weeks at the lower dose.

Missed doses: - If you miss a dose and it has been less than 4 days: Take it as soon as possible - If it has been more than 4 days: Skip the missed dose and take your next dose on the regular day - Do NOT double up doses - If you miss 2 or more consecutive weeks, contact your prescriber — you may need to re-titrate from a lower dose

UK prescriber contact: Most private UK providers offer clinical support between appointments. Keep your provider's contact details accessible and do not hesitate to reach out if you are struggling with side effects.

The maximum dose is not necessarily the optimal dose. Finding the right maintenance dose is a collaborative process between you and your prescriber.

Factors that influence optimal dose:

1. Weight loss rate: If you are losing 0.5–1kg per week consistently, that is considered excellent and there may be no need to increase further 2. Side effect tolerance: The best dose is the one that produces satisfactory results without intolerable side effects 3. Appetite control: If food noise is minimal and you can comfortably maintain a caloric deficit, the dose is working 4. Blood sugar control: For patients with type 2 diabetes, HbA1c improvements also guide dosing 5. Quality of life: Treatment should improve your quality of life, not diminish it with constant nausea

Distribution of maintenance doses in clinical practice: - 5mg: ~10% of patients (adequate for those with high GLP-1 sensitivity) - 7.5mg: ~15% of patients - 10mg: ~35% of patients (the most common maintenance dose) - 12.5mg: ~15% of patients - 15mg: ~25% of patients

The "dose optimisation" approach: Rather than automatically titrating to 15mg, many UK prescribers now use a "dose optimisation" strategy: 1. Titrate up until satisfactory weight loss is achieved (0.5–1kg/week) 2. Hold at that dose for 3–6 months 3. Only increase if weight loss plateaus and patient is tolerating the current dose well 4. This approach minimises side effects and may extend the duration of weight loss

Long-term considerations: - Weight loss typically plateaus at 9–12 months regardless of dose - The focus then shifts to weight maintenance - Some prescribers reduce the dose slightly during maintenance to improve tolerability - Stopping Mounjaro typically results in weight regain — discuss long-term plans with your prescriber

These practical recommendations are based on common experiences reported by UK patients and clinical best practice.

Storage and handling: - Unopened pens: Store in the fridge (2–8°C), not the freezer - Opened pens: Can be kept at room temperature (up to 30°C) for up to 21 days - Never freeze Mounjaro — it destroys the medication - When travelling, use an insulated cool bag with ice packs (not direct contact) - If you suspect temperature damage, do not use the pen — contact your provider

Injection technique: - Choose from: abdomen (most common), front of thigh, or back of upper arm - Rotate injection sites each week to prevent lipodystrophy - Clean the area with an alcohol swab and allow to dry - Press the pen firmly against the skin and hold the button for 10 seconds - Do not rub the injection site afterward - A small amount of blood or bruising is normal

Lifestyle optimisation during titration: - Protein priority: Aim for 1.2–1.6g per kilogram of body weight daily to preserve muscle mass - Resistance training: Essential to prevent muscle loss during rapid weight loss — at least 2 sessions per week - Hydration: At least 2 litres daily; more if experiencing GI side effects - Do not drastically cut calories: Mounjaro already reduces appetite; adding severe restriction causes fatigue, muscle loss and nutritional deficiencies

NHS prescriptions vs private: - If your GP takes over prescribing, the NHS prescription charge is just £9.90 per item - Ask your private prescriber for a detailed letter to your GP supporting continued prescribing - Some ICBs have shared care protocols allowing GP continuation after specialist initiation

*This guide is for educational purposes only. Mounjaro should only be used under medical supervision. Follow your prescriber's specific titration instructions, which may differ from the general guidance above.*